Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Biorest Ltd.

Massachusetts Institute of Technology

Zuli Holdings Ltd.

The Brigham and Women's Hospital, Inc.

Oregon Health & Science University

Cytec Technology Corporation

Hadasit Medical Research Services and Development Ltd.

Gershon Golomb

Haim D Danenberg

Eli Breuer

Elazer Reuven Edelman

Yoram Richter

Robert Samuel Langer

Alexander Levitzki

Aviv Gazit

Shmuel Banai

Edith Mathiowitz

Abraham J Domb

Cato T Laurencin

Reuven Reich

Ernest G Cravalho

Haim Danenberg

Frank D Boehmer

Hila Epstein

S David Gertz

Eyal Afergan

Johannes Waltenberger

Omid C Farokhzad

Saul Yedgar

Ivan Alferiev

Aleksandar Filip Radovic-Moreno

Gordon L Amidon

Weiwei Gao

Miron Krimsky

Jonah Sacha

Moshe Ligumski

Robert S Langer

Isaac Ginsburg

David Gertz

Archana Swami

David Ojcius

Benito Antonio Yard

Fokko Johannes Van Der Woude

Abd-al-Roof Higazi

Edit Schnitzer

Naama El-Hanany Rozen

Aviva Friedman-Ezra

Morey Schachter

Haigt Sacks

Yousef Najareh

Elia Fishbein

Michael Chorny

David Shoseyov

Yiffat Katz

David Shuseyov

Jonah B Sacha

Abd-Al-Roof Higazi

Haim Daneberg

A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells, the liposome loaded immune cells become activated and cross the blood barrier, and an effective amount of the pharmaceutical agent is released from the liposomes in the target organ of the subject.

Compositions and methods using same for delivering agents into a target organ protected by a blood barrier

A method of treating an acute myocardial infarction by administering to an individual an effective amount of a formulation which inhibits and/or depletes phagocytic cells with high specificity, thereby suppressing the inflammatory response that occurs during and following acute myocardial infarction. The formulation comprises an agent which is an intra-cellular inhibitor that is released within the targeted phagocytic cells, specifically macrophage/monocytes, and inhibits and/or destroys the macrophages and/or monocytes, thereby reducing the final zone of infarct and improving cardiac repair and myocardial remodeling. Since macrophages and monocytes possess the unique ability to phagocytose large bodies, the agent is formulated into a specific size such that it can enter cells primarily via phagocytosis. Thus, the specifically sized formulation selectively targets monocytes/macrophages. The formulation may comprise an encapsulated agent, an embedded agent or a particulate agent, wherein the formulation is of a specific size, such that it can enter cells primarily via phagocytosis. The formulation is preferably in the size range of 0.03-1.0 microns.

Method of treating acute myocardial infarction

The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.

Method of treating acute coronary syndromes

The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.

Use of bisphosphonates as HIV/AIDS adjunctive treatment

The present invention generally relates to polymers and particles, such as nanoparticles. The particles and polymers generally include one or more buffering components. Additionally, the particles and polymers may include two or more components that impart useful properties (functionalities). The particles and polymers, for example, may include a buffering component and a degradable component. As described herein, the particles and polymers may also include a hydrophilic component and/or a cleavable bond component. The particles and polymers described herein have been found to be particularly effective when used for delivery of one or more agents, such as one or more pharmaceutical agents. Other aspects of the invention are directed to methods of using or administering such particles or polymers, kits involving such particles or polymers, and the like. The present invention also relates to particles containing a cleavable bond component and one or more fluorescence resonance energy transfer (FRET) pairs as well as methods of detecting the cleavage of the cleavable bond component of such particles.

PH sensitive biodegradable polymeric particles for drug delivery

A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject.

Bisphosphonates for treating endometriosis

A nanoparticle capable of delivery of an encapsulated molecule into a living cell. The nanoparticle includes an encapsulation media and an isolated nucleic acid homolog sequence. The encapsulation media is primarily polymeric. The nanoparticles release the encapsulated molecule over an extended period of time. Further disclosed are pharmaceutical compositions and articles of manufacture including nanoparticles and methods of preparing and using the nanoparticles.

Nanoparticles containing polymeric nucleic acid homologs

The present invention provides a compound of the following formula I:R&#x2014;NH&#x2014;C(&#x2550;X)&#x2014;P(&#x2550;O)ORORincluding pharmaceutically acceptable salts, solvates, hydrates and polymorphs of the compounds of formula I, as well as geometrical isomers and optically active forms of the compounds of formula I and pharmaceutically acceptable salts, solvates, hydrates and polymorphs of said isomers and forms,wherein The invention further provides pharmaceutical compositions comprising the above compounds and their use in medicine.

Carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them

The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels. The surprisingly manifold pharmacological properties of the PL-conjugates allow for the invention, disclosed herein, of novel methods for the treatment of a diverse range of disease states, including obstructive respiratory disease, including asthma; colitis and Crohn's disease; central nervous system insult, including blood brain barrier compromise, ischemic stroke, and multiple sclerosis; contact dermatitis; psoriasis; cardiovascular disease, including ischemic conditions and prophylaxis for invasive vascular procedures; cellular proliferative disorders, including anti-tumor vasculogenesis, invasiveness, and metastases; anti-oxidant therapy; hemolytic syndromes; sepsis; acute respiratory distress syndrome; tissue transplant rejection syndromes; autoimmune disease; viral infection; and hypersensitivity conjunctivitis. The therapeutic methods of the invention include administration of phosphatidylethanolamine bound to carboxymethylcellulose, heparin, hyaluronic acid, polyethylene glycol, and hemaccel. Disclosed herein are also new compounds comprised of phospholipid moieties bound to low molecular weight monomers and dimers, including mono- and disaccharides, carboxylated disaccharides, mono- and dicarboxylic acids, salicylates, bile acids, and fatty acids.

Use of lipid conjugates in the treatment of disease

A method of inhibiting the activity or production of cytokines or growth factors associated with vascular restenosis, by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient. The cytokines and growth factors include, but are not limited to interleukin 1-&#x3b2;, matrix metalloproteinase-2, and platelet-derived growth factor &#x3b2; (PDGF&#x3b2;).

Method of inhibiting restenosis using bisphosphonates

A method of treating or preventing restenosis by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient. The active ingredient effects restenosis by inhibiting the growth and proliferation of the cell types involved in the restenotic cascade, such as macrophages/monocytes, fibroblasts and smooth-muscle cells.

Method of treating restenosis using bisphosphonate nanoparticles

PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same

Growing community of inventors

Efrat, Israel

Gershon Golomb